

KEYTRUDA® (PEMBROLIZUMAB) AND KEYTRUDA QLEX™ (PEMBROLIZUMAB AND BERAHYALURONIDASE) PRESCRIBER ORDER FORM

Patient Name:	Date of Birth:	Gender:
---------------	----------------	---------

Address:

Phone:	Height:	☐ inches ☐ cm	Weight:	☐ lbs. ☐ kg
--------	---------	---	---------	---

Clinical Information

Primary Diagnosis Description:	ICD-10 Code:
--------------------------------	--------------

Keytruda® (Pembrolizumab) Prescription

Keytruda® (Pembrolizumab) refill as directed x 1 year

- ☐ Infuse 200 mg IV over 30 minutes once every 3 weeks.
- ☐ Infuse 400 mg IV over 30 minutes once every 6 weeks.
- ☐ Other:

Keytruda QLEX® (Pembrolizumab and Berahyaluronidase) Prescription

Keytruda QLEX™ (Pembrolizumab and Berahyaluronidase) refill as directed x 1 year

- ☐ Inject 395 mg/4,800 units (2.4 mL) subcutaneously in the abdomen or thigh over 1 minute every 3 weeks
- ☐ Inject 790 mg/9,600 units (4.8 mL) subcutaneously in the abdomen or thigh over 2 minutes every 6 weeks
- ☐ Other:

Ancillary Orders

Anaphylaxis Orders

- Epinephrine 0.3 mg (> 30 kg), 0.15 mg (15 to 30 kg), or 0.01 mg/kg (< 15 kg) SUBQ or IM x 1; repeat x 1 in 5 to 15 min PRN.
- Diphenhydramine 25 mg (> 30 kg) or 1.25 mg/kg (≤ 30 kg) IV or IM; repeat x 1 in 15 min PRN no improvement.
- 0.9% Sodium Chloride 500 mL (> 30 kg) or 250 mL (≤ 30 kg) IV at KVO rate PRN anaphylaxis.
- Skilled Nursing to establish peripheral IV access as needed to manage anaphylaxis.

Pre-Medication Orders

- ☐ Acetaminophen 650 mg PO 30 min before infusion, may repeat every 4 to 6 hours as needed for fever or mild discomfort.
- ☐ Diphenhydramine 25 mg PO 30 min before infusion, may repeat every 4 to 6 hours as needed for mild to moderate allergic reactions.
- ☐ Other:

IV Flush Orders

- ☐ Peripheral: 0.9% Sodium Chloride 3 to 5 mL pre-/post-use.
- ☐ PICC and Central Tunneled/Non-Tunneled: 0.9% Sodium Chloride 5 to 10 mL pre-/post-use, 5 mL pre-lab draw, and 10 mL post-lab draw.
Heparin 10 unit/mL) 5 mL or (100 unit/mL) post-use.
For maintenance, heparin (10 unit/mL) 5 mL or (100 unit/mL) 3 mL every 24 hr.
- ☐ Implanted Port: 0.9% Sodium Chloride 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw.
Heparin (100 unit/mL) 3 to 5 mL post-use.
For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr. if accessed or weekly to monthly if not accessed.
- ☐ Valved Catheters: 0.9% Sodium Chloride 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw.
For maintenance, 0.9% Sodium Chloride 5 to 10 mL at least weekly.

Lab Orders

- ☐ No labs ordered at this time.
- ☐ Other:

Skilled nurse to assess and administer via access device as indicated above. Nurse will provide ongoing support as needed.

Refill above ancillary orders as directed x 1 year. If patient is seen within a provider led infusion clinic, Option Care Health's infusion reaction management policy, skilled nursing plan of treatment, and IV flush administration will be followed per provider oversight. No individual anaphylaxis kit will be dispensed.

I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.

Prescriber Signature: _____ Date: _____

Prescriber Information

Prescriber Name:	Phone:	Fax:
Address:	NPI:	
City, State:	Zip:	Office Contact:

Fax completed form, insurance information, and clinical documentation to: 713-983-4647

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. **IMPORTANT WARNING:** This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.

Not valid for use for patients residing in Arizona, New York, and Wisconsin